Future Market Insights (FMI)’ updated report on the asthma treatment market highlights several opportunities and growth prospects for the coming decade. As per the report, the asthma treatment market is set to surge from USD 28.0 billion in 2024 and USD 46.0 billion by 2034. The report reflects a robust CAGR of 5.1% between 2024 and 2034, inferring strong market growth.
| Attributes | Key Insights |
|---|---|
| Global Asthma Treatment Market Size (2024E) | USD 28.0 billion |
| Market Value (2034F) | USD 46.0 billion |
| Value-based CAGR (2024 to 2034) | 5.1% |
The increasing incidence of asthma, growing knowledge about asthma medications, and advancements in asthma treatment choices are projected to spur market growth. The industry is further propelled by environmental factors such as air pollution, allergens, and lifestyle changes, which contribute to the surged prevalence of asthma worldwide.
Precision medicine is gaining traction in the asthma treatment industry as demand for individualized asthma medications increases. Mobile applications, smart inhalers, and wearable devices are improving tailored asthma therapy by allowing for real-time monitoring of symptoms, medication adherence, and lung function.
This accurate data gathering helps healthcare practitioners and professionals to understand each patient's asthma management better and offer appropriate treatment solutions.
Remote monitoring and telemedicine services are further estimated to enhance personalized treatment for patients in remote and underdeveloped areas. Pharmaceutical companies and research organizations are investing in innovating new drugs and therapies to meet the diverse needs of asthma patients globally.
Public health initiatives and awareness campaigns are further boosting market development. Urbanization, industrialization, genetic susceptibility, and family history of asthma are set to contribute to mounting asthma prevalence, creating an environment favorable for market growth.
From 2019 to 2023, bronchodilators such as theophylline and beta-agonists were primarily considered as asthma treatments, providing relief from symptoms. During 2019 and 2023, the market grew at a CAGR of 6.8%. Development in genetics and biomarker research has enabled personalized asthma treatment, optimizing its efficacy and minimizing side effects.
Digital health technologies, such as asthma management mobile apps, smart inhalers, and telemedicine services, further enabled better monitoring of asthma symptoms, medication adherence, and remote patient management.
Smart inhalers, smartphone applications, and telemedicine are improving asthma therapy by allowing for remote monitoring, medication adherence, and increased patient awareness and education. Preventive methods, such as environmental trigger reduction and lifestyle modifications aimed at reducing exacerbations and improving long-term treatment results, are set to fuel the market development.
Combination inhalers with bronchodilators and corticosteroids are gaining traction in asthma management due to their ease of use and improved patient outcomes. Healthcare policies, reimbursement structures, and value-based care initiatives are set to fuel asthma treatment adoption globally.
Leading companies and producers are focusing on developing novel therapeutic targets, drug delivery systems, and alternative treatments, propelling market development. The shift toward patient-centric care models, self-management education, and empowerment is gaining momentum in several emerging markets.
The section below highlights the projected growth rates of leading countries. Among these, South Korea is set to remain a highly lucrative market, exhibiting a CAGR of 7.2%. Japan and the United Kingdom are estimated to follow with CAGRs of 6.8% and 6.3%, respectively.
| Countries | Projected CAGR (2024 to 2034) |
|---|---|
| United States | 5.4% |
| United Kingdom | 6.3% |
| China | 5.9% |
| South Korea | 7.2% |
| Japan | 6.8% |
The asthma treatment industry can be observed in the subsequent tables, which focus on the leading economies, consisting of South Korea, Japan, the United Kingdom, China, and the United States. A comprehensive evaluation demonstrates that the United States has enormous potential for growth in the market.
| Countries | Market Values (2034) |
|---|---|
| United States | USD 8.3 billion |
| United Kingdom | USD 1.9 billion |
| China | USD 7.3 billion |
| South Korea | USD 3.0 billion |
| Japan | USD 5.2 billion |
The United States is set to dominate the market by 2034, surging at a CAGR of 5.4%. Asthma, a common non-communicable disease in the United States, accounts for around 73% of outpatient clinic visits, creating a wide target population for effective asthma therapeutics.
Established healthcare infrastructure and increasing asthma prevalence in the United States are the key factors propelling market growth. The United States is further projected to grow significantly due to improved government reforms, a rising geriatric population, increasing healthcare expenditure, and growing consumer awareness about lung diseases.
By 2034, China is projected to grow substantially at a CAGR of 5.9%. Government initiatives, subsidies, and reimbursement policies to improve treatment quality, promote evidence-based practices, and reduce healthcare inconsistencies are influencing asthma therapy adoption in China.
Leading companies in China are focusing on research & development to innovate new therapeutic treatments, improve drug delivery systems, and understand asthma pathophysiology to reach wider customers.
The competitive asthma care market in China encourages innovation through collaborations and partnerships between industry stakeholders, academia, and patient advocacy groups.
Japan is projected to propel due to factors such as high asthma prevalence, increased consumer awareness, and innovations in treatment options. Developments in biologic medications and targeted therapies, which offer improved efficacy and fewer side effects, are estimated to fuel growth in the market.
The market in Japan is further anticipated to be influenced by increased FDA endorsements and key market strategies such as collaboration, mergers, and partnerships among local and international companies. The market's development is projected to be accelerated by key players intensifying their geographical presence in emerging nations. By 2034, Japan is projected to reach USD 5.2 billion.
South Korea is home to several leading pharmaceutical companies specializing in asthma treatment, medication development, and manufacturing. These companies contribute to innovative asthma management therapies, propelling market growth in South Korea. South Korea is projected to reach a market valuation of USD 3.0 billion in 2034.
South Korea's regulatory framework and favorable government reimbursement system encourage asthma treatment adoption, providing patients with a wide range of treatment options and fueling market reach.
South Korea is a leading center for asthma research and clinical trials, involving academic institutions, research centers, and healthcare organizations to develop new treatment methods.
The segmented market analysis is included in the subsequent section. Based on comprehensive studies, the inhaler segment is dominating the product category. Likewise, the oral segment is commanding the route of administration category.
| Segment | Value CAGR (2024 to 2034) |
|---|---|
| Inhalers (Product) | 4.8% |
| Oral (Route of Administration) | 4.6% |
The inhalers segment, with its reliability, versatility, portability, and cost-effectiveness, is projected to lead the product segment by 2034. The growing prevalence of asthma and COPD, along with the need for emergency treatment alternatives, is propelling the segment’s growth.
The development of progressive products, such as Trelegy Ellipta, a triple therapy inhaler approved in the United States, is also projected to fuel segment growth. Based on product, the inhaler segment is set to surge at a CAGR of 4.8% by 2034.
Based on the route of administration, the oral segment is set to rise at 4.6% CAGR by 2034. The segment is projected to witness a leading growth rate from 2024 to 2034 due to its convenience and efficacy.
Oral medications, taken by mouth and absorbed through the digestive system, are well-preferred and easy to use, making them popular among patients and healthcare providers. The convenience, effectiveness, and versatility of the oral route of administration make the segment a valuable tool for managing asthma, boosting the segment's growth.
Leading pharmaceutical companies are inclined toward research & development to surge their market reach while emerging biotech companies innovate targeted treatments to uphold their positions. Market growth relies on regulatory adherence, diagnostic research, strategic partnerships, and adapting to evolving consumer tastes.
For instance
Table 1: Global Market Value (US$ million) Forecast by Region, 2019 to 2034
Table 2: Global Market Volume (Units) Forecast by Region, 2019 to 2034
Table 3: Global Market Value (US$ million) Forecast by Drug Class, 2019 to 2034
Table 4: Global Market Volume (Units) Forecast by Drug Class, 2019 to 2034
Table 5: Global Market Value (US$ million) Forecast by Product, 2019 to 2034
Table 6: Global Market Volume (Units) Forecast by Product, 2019 to 2034
Table 7: Global Market Value (US$ million) Forecast by Route of Administration, 2019 to 2034
Table 8: Global Market Volume (Units) Forecast by Route of Administration, 2019 to 2034
Table 9: North America Market Value (US$ million) Forecast by Country, 2019 to 2034
Table 10: North America Market Volume (Units) Forecast by Country, 2019 to 2034
Table 11: North America Market Value (US$ million) Forecast by Drug Class, 2019 to 2034
Table 12: North America Market Volume (Units) Forecast by Drug Class, 2019 to 2034
Table 13: North America Market Value (US$ million) Forecast by Product, 2019 to 2034
Table 14: North America Market Volume (Units) Forecast by Product, 2019 to 2034
Table 15: North America Market Value (US$ million) Forecast by Route of Administration, 2019 to 2034
Table 16: North America Market Volume (Units) Forecast by Route of Administration, 2019 to 2034
Table 17: Latin America Market Value (US$ million) Forecast by Country, 2019 to 2034
Table 18: Latin America Market Volume (Units) Forecast by Country, 2019 to 2034
Table 19: Latin America Market Value (US$ million) Forecast by Drug Class, 2019 to 2034
Table 20: Latin America Market Volume (Units) Forecast by Drug Class, 2019 to 2034
Table 21: Latin America Market Value (US$ million) Forecast by Product, 2019 to 2034
Table 22: Latin America Market Volume (Units) Forecast by Product, 2019 to 2034
Table 23: Latin America Market Value (US$ million) Forecast by Route of Administration, 2019 to 2034
Table 24: Latin America Market Volume (Units) Forecast by Route of Administration, 2019 to 2034
Table 25: Western Europe Market Value (US$ million) Forecast by Country, 2019 to 2034
Table 26: Western Europe Market Volume (Units) Forecast by Country, 2019 to 2034
Table 27: Western Europe Market Value (US$ million) Forecast by Drug Class, 2019 to 2034
Table 28: Western Europe Market Volume (Units) Forecast by Drug Class, 2019 to 2034
Table 29: Western Europe Market Value (US$ million) Forecast by Product, 2019 to 2034
Table 30: Western Europe Market Volume (Units) Forecast by Product, 2019 to 2034
Table 31: Western Europe Market Value (US$ million) Forecast by Route of Administration, 2019 to 2034
Table 32: Western Europe Market Volume (Units) Forecast by Route of Administration, 2019 to 2034
Table 33: Eastern Europe Market Value (US$ million) Forecast by Country, 2019 to 2034
Table 34: Eastern Europe Market Volume (Units) Forecast by Country, 2019 to 2034
Table 35: Eastern Europe Market Value (US$ million) Forecast by Drug Class, 2019 to 2034
Table 36: Eastern Europe Market Volume (Units) Forecast by Drug Class, 2019 to 2034
Table 37: Eastern Europe Market Value (US$ million) Forecast by Product, 2019 to 2034
Table 38: Eastern Europe Market Volume (Units) Forecast by Product, 2019 to 2034
Table 39: Eastern Europe Market Value (US$ million) Forecast by Route of Administration, 2019 to 2034
Table 40: Eastern Europe Market Volume (Units) Forecast by Route of Administration, 2019 to 2034
Table 41: South Asia and Pacific Market Value (US$ million) Forecast by Country, 2019 to 2034
Table 42: South Asia and Pacific Market Volume (Units) Forecast by Country, 2019 to 2034
Table 43: South Asia and Pacific Market Value (US$ million) Forecast by Drug Class, 2019 to 2034
Table 44: South Asia and Pacific Market Volume (Units) Forecast by Drug Class, 2019 to 2034
Table 45: South Asia and Pacific Market Value (US$ million) Forecast by Product, 2019 to 2034
Table 46: South Asia and Pacific Market Volume (Units) Forecast by Product, 2019 to 2034
Table 47: South Asia and Pacific Market Value (US$ million) Forecast by Route of Administration, 2019 to 2034
Table 48: South Asia and Pacific Market Volume (Units) Forecast by Route of Administration, 2019 to 2034
Table 49: East Asia Market Value (US$ million) Forecast by Country, 2019 to 2034
Table 50: East Asia Market Volume (Units) Forecast by Country, 2019 to 2034
Table 51: East Asia Market Value (US$ million) Forecast by Drug Class, 2019 to 2034
Table 52: East Asia Market Volume (Units) Forecast by Drug Class, 2019 to 2034
Table 53: East Asia Market Value (US$ million) Forecast by Product, 2019 to 2034
Table 54: East Asia Market Volume (Units) Forecast by Product, 2019 to 2034
Table 55: East Asia Market Value (US$ million) Forecast by Route of Administration, 2019 to 2034
Table 56: East Asia Market Volume (Units) Forecast by Route of Administration, 2019 to 2034
Table 57: Middle East and Africa Market Value (US$ million) Forecast by Country, 2019 to 2034
Table 58: Middle East and Africa Market Volume (Units) Forecast by Country, 2019 to 2034
Table 59: Middle East and Africa Market Value (US$ million) Forecast by Drug Class, 2019 to 2034
Table 60: Middle East and Africa Market Volume (Units) Forecast by Drug Class, 2019 to 2034
Table 61: Middle East and Africa Market Value (US$ million) Forecast by Product, 2019 to 2034
Table 62: Middle East and Africa Market Volume (Units) Forecast by Product, 2019 to 2034
Table 63: Middle East and Africa Market Value (US$ million) Forecast by Route of Administration, 2019 to 2034
Table 64: Middle East and Africa Market Volume (Units) Forecast by Route of Administration, 2019 to 2034
Figure 1: Global Market Value (US$ million) by Drug Class, 2024 to 2034
Figure 2: Global Market Value (US$ million) by Product, 2024 to 2034
Figure 3: Global Market Value (US$ million) by Route of Administration, 2024 to 2034
Figure 4: Global Market Value (US$ million) by Region, 2024 to 2034
Figure 5: Global Market Value (US$ million) Analysis by Region, 2019 to 2034
Figure 6: Global Market Volume (Units) Analysis by Region, 2019 to 2034
Figure 7: Global Market Value Share (%) and BPS Analysis by Region, 2024 to 2034
Figure 8: Global Market Y-o-Y Growth (%) Projections by Region, 2024 to 2034
Figure 9: Global Market Value (US$ million) Analysis by Drug Class, 2019 to 2034
Figure 10: Global Market Volume (Units) Analysis by Drug Class, 2019 to 2034
Figure 11: Global Market Value Share (%) and BPS Analysis by Drug Class, 2024 to 2034
Figure 12: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2024 to 2034
Figure 13: Global Market Value (US$ million) Analysis by Product, 2019 to 2034
Figure 14: Global Market Volume (Units) Analysis by Product, 2019 to 2034
Figure 15: Global Market Value Share (%) and BPS Analysis by Product, 2024 to 2034
Figure 16: Global Market Y-o-Y Growth (%) Projections by Product, 2024 to 2034
Figure 17: Global Market Value (US$ million) Analysis by Route of Administration, 2019 to 2034
Figure 18: Global Market Volume (Units) Analysis by Route of Administration, 2019 to 2034
Figure 19: Global Market Value Share (%) and BPS Analysis by Route of Administration, 2024 to 2034
Figure 20: Global Market Y-o-Y Growth (%) Projections by Route of Administration, 2024 to 2034
Figure 21: Global Market Attractiveness by Drug Class, 2024 to 2034
Figure 22: Global Market Attractiveness by Product, 2024 to 2034
Figure 23: Global Market Attractiveness by Route of Administration, 2024 to 2034
Figure 24: Global Market Attractiveness by Region, 2024 to 2034
Figure 25: North America Market Value (US$ million) by Drug Class, 2024 to 2034
Figure 26: North America Market Value (US$ million) by Product, 2024 to 2034
Figure 27: North America Market Value (US$ million) by Route of Administration, 2024 to 2034
Figure 28: North America Market Value (US$ million) by Country, 2024 to 2034
Figure 29: North America Market Value (US$ million) Analysis by Country, 2019 to 2034
Figure 30: North America Market Volume (Units) Analysis by Country, 2019 to 2034
Figure 31: North America Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 32: North America Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 33: North America Market Value (US$ million) Analysis by Drug Class, 2019 to 2034
Figure 34: North America Market Volume (Units) Analysis by Drug Class, 2019 to 2034
Figure 35: North America Market Value Share (%) and BPS Analysis by Drug Class, 2024 to 2034
Figure 36: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2024 to 2034
Figure 37: North America Market Value (US$ million) Analysis by Product, 2019 to 2034
Figure 38: North America Market Volume (Units) Analysis by Product, 2019 to 2034
Figure 39: North America Market Value Share (%) and BPS Analysis by Product, 2024 to 2034
Figure 40: North America Market Y-o-Y Growth (%) Projections by Product, 2024 to 2034
Figure 41: North America Market Value (US$ million) Analysis by Route of Administration, 2019 to 2034
Figure 42: North America Market Volume (Units) Analysis by Route of Administration, 2019 to 2034
Figure 43: North America Market Value Share (%) and BPS Analysis by Route of Administration, 2024 to 2034
Figure 44: North America Market Y-o-Y Growth (%) Projections by Route of Administration, 2024 to 2034
Figure 45: North America Market Attractiveness by Drug Class, 2024 to 2034
Figure 46: North America Market Attractiveness by Product, 2024 to 2034
Figure 47: North America Market Attractiveness by Route of Administration, 2024 to 2034
Figure 48: North America Market Attractiveness by Country, 2024 to 2034
Figure 49: Latin America Market Value (US$ million) by Drug Class, 2024 to 2034
Figure 50: Latin America Market Value (US$ million) by Product, 2024 to 2034
Figure 51: Latin America Market Value (US$ million) by Route of Administration, 2024 to 2034
Figure 52: Latin America Market Value (US$ million) by Country, 2024 to 2034
Figure 53: Latin America Market Value (US$ million) Analysis by Country, 2019 to 2034
Figure 54: Latin America Market Volume (Units) Analysis by Country, 2019 to 2034
Figure 55: Latin America Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 57: Latin America Market Value (US$ million) Analysis by Drug Class, 2019 to 2034
Figure 58: Latin America Market Volume (Units) Analysis by Drug Class, 2019 to 2034
Figure 59: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2024 to 2034
Figure 60: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2024 to 2034
Figure 61: Latin America Market Value (US$ million) Analysis by Product, 2019 to 2034
Figure 62: Latin America Market Volume (Units) Analysis by Product, 2019 to 2034
Figure 63: Latin America Market Value Share (%) and BPS Analysis by Product, 2024 to 2034
Figure 64: Latin America Market Y-o-Y Growth (%) Projections by Product, 2024 to 2034
Figure 65: Latin America Market Value (US$ million) Analysis by Route of Administration, 2019 to 2034
Figure 66: Latin America Market Volume (Units) Analysis by Route of Administration, 2019 to 2034
Figure 67: Latin America Market Value Share (%) and BPS Analysis by Route of Administration, 2024 to 2034
Figure 68: Latin America Market Y-o-Y Growth (%) Projections by Route of Administration, 2024 to 2034
Figure 69: Latin America Market Attractiveness by Drug Class, 2024 to 2034
Figure 70: Latin America Market Attractiveness by Product, 2024 to 2034
Figure 71: Latin America Market Attractiveness by Route of Administration, 2024 to 2034
Figure 72: Latin America Market Attractiveness by Country, 2024 to 2034
Figure 73: Western Europe Market Value (US$ million) by Drug Class, 2024 to 2034
Figure 74: Western Europe Market Value (US$ million) by Product, 2024 to 2034
Figure 75: Western Europe Market Value (US$ million) by Route of Administration, 2024 to 2034
Figure 76: Western Europe Market Value (US$ million) by Country, 2024 to 2034
Figure 77: Western Europe Market Value (US$ million) Analysis by Country, 2019 to 2034
Figure 78: Western Europe Market Volume (Units) Analysis by Country, 2019 to 2034
Figure 79: Western Europe Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 80: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 81: Western Europe Market Value (US$ million) Analysis by Drug Class, 2019 to 2034
Figure 82: Western Europe Market Volume (Units) Analysis by Drug Class, 2019 to 2034
Figure 83: Western Europe Market Value Share (%) and BPS Analysis by Drug Class, 2024 to 2034
Figure 84: Western Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2024 to 2034
Figure 85: Western Europe Market Value (US$ million) Analysis by Product, 2019 to 2034
Figure 86: Western Europe Market Volume (Units) Analysis by Product, 2019 to 2034
Figure 87: Western Europe Market Value Share (%) and BPS Analysis by Product, 2024 to 2034
Figure 88: Western Europe Market Y-o-Y Growth (%) Projections by Product, 2024 to 2034
Figure 89: Western Europe Market Value (US$ million) Analysis by Route of Administration, 2019 to 2034
Figure 90: Western Europe Market Volume (Units) Analysis by Route of Administration, 2019 to 2034
Figure 91: Western Europe Market Value Share (%) and BPS Analysis by Route of Administration, 2024 to 2034
Figure 92: Western Europe Market Y-o-Y Growth (%) Projections by Route of Administration, 2024 to 2034
Figure 93: Western Europe Market Attractiveness by Drug Class, 2024 to 2034
Figure 94: Western Europe Market Attractiveness by Product, 2024 to 2034
Figure 95: Western Europe Market Attractiveness by Route of Administration, 2024 to 2034
Figure 96: Western Europe Market Attractiveness by Country, 2024 to 2034
Figure 97: Eastern Europe Market Value (US$ million) by Drug Class, 2024 to 2034
Figure 98: Eastern Europe Market Value (US$ million) by Product, 2024 to 2034
Figure 99: Eastern Europe Market Value (US$ million) by Route of Administration, 2024 to 2034
Figure 100: Eastern Europe Market Value (US$ million) by Country, 2024 to 2034
Figure 101: Eastern Europe Market Value (US$ million) Analysis by Country, 2019 to 2034
Figure 102: Eastern Europe Market Volume (Units) Analysis by Country, 2019 to 2034
Figure 103: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 104: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 105: Eastern Europe Market Value (US$ million) Analysis by Drug Class, 2019 to 2034
Figure 106: Eastern Europe Market Volume (Units) Analysis by Drug Class, 2019 to 2034
Figure 107: Eastern Europe Market Value Share (%) and BPS Analysis by Drug Class, 2024 to 2034
Figure 108: Eastern Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2024 to 2034
Figure 109: Eastern Europe Market Value (US$ million) Analysis by Product, 2019 to 2034
Figure 110: Eastern Europe Market Volume (Units) Analysis by Product, 2019 to 2034
Figure 111: Eastern Europe Market Value Share (%) and BPS Analysis by Product, 2024 to 2034
Figure 112: Eastern Europe Market Y-o-Y Growth (%) Projections by Product, 2024 to 2034
Figure 113: Eastern Europe Market Value (US$ million) Analysis by Route of Administration, 2019 to 2034
Figure 114: Eastern Europe Market Volume (Units) Analysis by Route of Administration, 2019 to 2034
Figure 115: Eastern Europe Market Value Share (%) and BPS Analysis by Route of Administration, 2024 to 2034
Figure 116: Eastern Europe Market Y-o-Y Growth (%) Projections by Route of Administration, 2024 to 2034
Figure 117: Eastern Europe Market Attractiveness by Drug Class, 2024 to 2034
Figure 118: Eastern Europe Market Attractiveness by Product, 2024 to 2034
Figure 119: Eastern Europe Market Attractiveness by Route of Administration, 2024 to 2034
Figure 120: Eastern Europe Market Attractiveness by Country, 2024 to 2034
Figure 121: South Asia and Pacific Market Value (US$ million) by Drug Class, 2024 to 2034
Figure 122: South Asia and Pacific Market Value (US$ million) by Product, 2024 to 2034
Figure 123: South Asia and Pacific Market Value (US$ million) by Route of Administration, 2024 to 2034
Figure 124: South Asia and Pacific Market Value (US$ million) by Country, 2024 to 2034
Figure 125: South Asia and Pacific Market Value (US$ million) Analysis by Country, 2019 to 2034
Figure 126: South Asia and Pacific Market Volume (Units) Analysis by Country, 2019 to 2034
Figure 127: South Asia and Pacific Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 128: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 129: South Asia and Pacific Market Value (US$ million) Analysis by Drug Class, 2019 to 2034
Figure 130: South Asia and Pacific Market Volume (Units) Analysis by Drug Class, 2019 to 2034
Figure 131: South Asia and Pacific Market Value Share (%) and BPS Analysis by Drug Class, 2024 to 2034
Figure 132: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Drug Class, 2024 to 2034
Figure 133: South Asia and Pacific Market Value (US$ million) Analysis by Product, 2019 to 2034
Figure 134: South Asia and Pacific Market Volume (Units) Analysis by Product, 2019 to 2034
Figure 135: South Asia and Pacific Market Value Share (%) and BPS Analysis by Product, 2024 to 2034
Figure 136: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Product, 2024 to 2034
Figure 137: South Asia and Pacific Market Value (US$ million) Analysis by Route of Administration, 2019 to 2034
Figure 138: South Asia and Pacific Market Volume (Units) Analysis by Route of Administration, 2019 to 2034
Figure 139: South Asia and Pacific Market Value Share (%) and BPS Analysis by Route of Administration, 2024 to 2034
Figure 140: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Route of Administration, 2024 to 2034
Figure 141: South Asia and Pacific Market Attractiveness by Drug Class, 2024 to 2034
Figure 142: South Asia and Pacific Market Attractiveness by Product, 2024 to 2034
Figure 143: South Asia and Pacific Market Attractiveness by Route of Administration, 2024 to 2034
Figure 144: South Asia and Pacific Market Attractiveness by Country, 2024 to 2034
Figure 145: East Asia Market Value (US$ million) by Drug Class, 2024 to 2034
Figure 146: East Asia Market Value (US$ million) by Product, 2024 to 2034
Figure 147: East Asia Market Value (US$ million) by Route of Administration, 2024 to 2034
Figure 148: East Asia Market Value (US$ million) by Country, 2024 to 2034
Figure 149: East Asia Market Value (US$ million) Analysis by Country, 2019 to 2034
Figure 150: East Asia Market Volume (Units) Analysis by Country, 2019 to 2034
Figure 151: East Asia Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 152: East Asia Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 153: East Asia Market Value (US$ million) Analysis by Drug Class, 2019 to 2034
Figure 154: East Asia Market Volume (Units) Analysis by Drug Class, 2019 to 2034
Figure 155: East Asia Market Value Share (%) and BPS Analysis by Drug Class, 2024 to 2034
Figure 156: East Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2024 to 2034
Figure 157: East Asia Market Value (US$ million) Analysis by Product, 2019 to 2034
Figure 158: East Asia Market Volume (Units) Analysis by Product, 2019 to 2034
Figure 159: East Asia Market Value Share (%) and BPS Analysis by Product, 2024 to 2034
Figure 160: East Asia Market Y-o-Y Growth (%) Projections by Product, 2024 to 2034
Figure 161: East Asia Market Value (US$ million) Analysis by Route of Administration, 2019 to 2034
Figure 162: East Asia Market Volume (Units) Analysis by Route of Administration, 2019 to 2034
Figure 163: East Asia Market Value Share (%) and BPS Analysis by Route of Administration, 2024 to 2034
Figure 164: East Asia Market Y-o-Y Growth (%) Projections by Route of Administration, 2024 to 2034
Figure 165: East Asia Market Attractiveness by Drug Class, 2024 to 2034
Figure 166: East Asia Market Attractiveness by Product, 2024 to 2034
Figure 167: East Asia Market Attractiveness by Route of Administration, 2024 to 2034
Figure 168: East Asia Market Attractiveness by Country, 2024 to 2034
Figure 169: Middle East and Africa Market Value (US$ million) by Drug Class, 2024 to 2034
Figure 170: Middle East and Africa Market Value (US$ million) by Product, 2024 to 2034
Figure 171: Middle East and Africa Market Value (US$ million) by Route of Administration, 2024 to 2034
Figure 172: Middle East and Africa Market Value (US$ million) by Country, 2024 to 2034
Figure 173: Middle East and Africa Market Value (US$ million) Analysis by Country, 2019 to 2034
Figure 174: Middle East and Africa Market Volume (Units) Analysis by Country, 2019 to 2034
Figure 175: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 176: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 177: Middle East and Africa Market Value (US$ million) Analysis by Drug Class, 2019 to 2034
Figure 178: Middle East and Africa Market Volume (Units) Analysis by Drug Class, 2019 to 2034
Figure 179: Middle East and Africa Market Value Share (%) and BPS Analysis by Drug Class, 2024 to 2034
Figure 180: Middle East and Africa Market Y-o-Y Growth (%) Projections by Drug Class, 2024 to 2034
Figure 181: Middle East and Africa Market Value (US$ million) Analysis by Product, 2019 to 2034
Figure 182: Middle East and Africa Market Volume (Units) Analysis by Product, 2019 to 2034
Figure 183: Middle East and Africa Market Value Share (%) and BPS Analysis by Product, 2024 to 2034
Figure 184: Middle East and Africa Market Y-o-Y Growth (%) Projections by Product, 2024 to 2034
Figure 185: Middle East and Africa Market Value (US$ million) Analysis by Route of Administration, 2019 to 2034
Figure 186: Middle East and Africa Market Volume (Units) Analysis by Route of Administration, 2019 to 2034
Figure 187: Middle East and Africa Market Value Share (%) and BPS Analysis by Route of Administration, 2024 to 2034
Figure 188: Middle East and Africa Market Y-o-Y Growth (%) Projections by Route of Administration, 2024 to 2034
Figure 189: Middle East and Africa Market Attractiveness by Drug Class, 2024 to 2034
Figure 190: Middle East and Africa Market Attractiveness by Product, 2024 to 2034
Figure 191: Middle East and Africa Market Attractiveness by Route of Administration, 2024 to 2034
Figure 192: Middle East and Africa Market Attractiveness by Country, 2024 to 2034
The market is set to reach USD 28.0 billion in 2024.
Demand for asthma treatment is slated to rise at a 5.1% CAGR by 2034.
The market is set to reach USD 46.0 billion in 2034.
Teva Pharmaceutical Industries Ltd, GSK plc, Merck & Co.Inc, and AstraZeneca are the key players.
The inhaler segment is estimated to hold a significant market share in 2024.
Explore Similar Insights
Asthma Treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
